Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 31:11:2081-2094.
doi: 10.2147/IDR.S176519. eCollection 2018.

Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis

Cameron J Phillips  1   2   3   4 , Alice J Wisdom  5 , Ross A McKinnon  2   3   6 , Richard J Woodman  7 , David L Gordon  2   8   9
Affiliations
Review

Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis

Cameron J Phillips et al. Infect Drug Resist. .

Abstract

Purpose: Vancomycin prescribing requires individualized dosing and monitoring to ensure efficacy, limit toxicity, and minimize resistance. Although there are nationally endorsed guidelines from several countries addressing the complexities of vancomycin dosing and monitoring, there is limited consideration of how to implement these recommendations effectively.

Methods: We conducted a systematic search of multiple databases to identify relevant comparative studies describing the impact of interventions of educational meetings, implementation of guidelines, and dissemination of educational material on vancomycin dosing, monitoring, and nephrotoxicity. Effect size was assessed using ORs and pooled data analyzed using forest plots to provide overall effect measures.

Results: Six studies were included. All studies included educational meetings. Two studies used implementation of guidance, educational meetings, and dissemination of educational materials, one used guidance and educational meetings, one educational meetings and dissemination of educational materials, and two used educational meetings solely. Effect sizes for individual studies were more likely to be significant for multifaceted interventions. In meta-analysis, the overall effect of interventions on outcome measures of vancomycin dosing was OR 2.50 (95% CI 1.29-4.84); P< 0.01. A higher proportion of sampling at steady-state concentration was seen following intervention (OR 1.95, 95% CI 1.26-3.02; P<0.01). Interventions had no effect on appropriate timing of trough sample (OR 2.02, 95% CI 0.72-5.72; P=0.18), attaining target concentration in patients (OR 1.50, 95% CI 0.49-4.63; P=0.48, or nephrotoxicity (OR 0.75, 95% CI 0.42-1.34; P=0.33).

Conclusion: Multifaceted interventions are effective overall in improving the complex task of dosing vancomycin, as well as some vancomycin-monitoring outcome measures. However, the resulting impact of these interventions on efficacy and toxicity requires further investigation. These findings may be helpful to those charged with designing implementation strategies for vancomycin guidelines or complex prescribing processes in hospitals.

Keywords: drug monitoring; education; guideline; implementation; intervention; prescribing; systematic review; vancomycin.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA study flow diagram.
Figure 2
Figure 2
Quality of included studies: ROBINS-I (risk of bias assessment in nonrandomized studies – interventions).
Figure 3
Figure 3
Effect of interventions on vancomycin dosing.
Figure 4
Figure 4
Effect of interventions on vancomycin therapeutic drug monitoring.
Figure 5
Figure 5
Effect of interventions on supratherapeutic concentrations and nephrotoxicity in patients receiving vancomycin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Moellering RC. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3–S4. - PubMed
    1. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl 1):S35–S39. - PubMed
    1. Giuliano C, Giulano C, Haase KK, Hall R. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. Expert Rev Anti Infect Ther. 2010;8(1):95–106. - PMC - PubMed
    1. Ye ZK, Tang HL, Zhai SD. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One. 2013;8(10):e77169. - PMC - PubMed
    1. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99–139. - PMC - PubMed